Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...
Regeneron price target lowered to $925 from $950 at Oppenheimer
Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...
Zacks Investment Research on MSN5d
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...